Reported Physical Symptoms During Screening Echocardiography Are Not Associated With Presence of Suspected Hypertrophic Cardiomyopathy.

Q3 Medicine

Critical Pathways in Cardiology Pub Date : 2024-09-01 Epub Date: 2024-04-10 DOI:10.1097/HPC.0000000000000358

Mohammad Reza Movahed, Ashkan Bahrami, Sharon Bates

{"title":"Reported Physical Symptoms During Screening Echocardiography Are Not Associated With Presence of Suspected Hypertrophic Cardiomyopathy.","authors":"Mohammad Reza Movahed, Ashkan Bahrami, Sharon Bates","doi":"10.1097/HPC.0000000000000358","DOIUrl":null,"url":null,"abstract":"Background: The prevalence of hypertrophic cardiomyopathy (HCM) can be silent and can present with sudden death as the first manifestation of this disease. The goal of this study was to evaluate any association between reported physical symptoms with the presence of suspected HCM.Method: The Anthony Bates Foundation has been performing screening echocardiography across the United States for prevention of sudden death since 2001. A total of 4120 subjects between the ages of 4 and 79 underwent echocardiographic screening. We evaluated any association between various symptoms and suspected HCM defined as any left ventricular wall thickness³ ≥15 mm.Results: The total prevalence of suspected HCM in the entire study population was 1.1%. The presence of physical symptoms was not associated with HCM (chest pain in 4.3% of participants with HCM vs. 9.9% of the control, P = 0.19, palpitation in 4.3% of participants with HCM vs. 7.3% of the control, P = 0.41, shortness of breath in 6.4% of participant with HCM vs. 11.7% of the control, P = 0.26, lightheadedness in 4.3% of participant with HCM vs. 13.1% of the control, P = 0.07, ankle swelling in 2.1% of participant with HCM vs. 4.0% of the control, P = 0.52, dizziness in 8.5% of participant with HCM vs. 12.2% of the control, P = 0.44).Conclusions: Echocardiographic presence of suspected HCM is not associated with a higher prevalence of physical symptoms in the participants undergoing screening echocardiography.","PeriodicalId":35914,"journal":{"name":"Critical Pathways in Cardiology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Critical Pathways in Cardiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/HPC.0000000000000358","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/4/10 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The prevalence of hypertrophic cardiomyopathy (HCM) can be silent and can present with sudden death as the first manifestation of this disease. The goal of this study was to evaluate any association between reported physical symptoms with the presence of suspected HCM.

Method: The Anthony Bates Foundation has been performing screening echocardiography across the United States for prevention of sudden death since 2001. A total of 4120 subjects between the ages of 4 and 79 underwent echocardiographic screening. We evaluated any association between various symptoms and suspected HCM defined as any left ventricular wall thickness³ ≥15 mm.

Results: The total prevalence of suspected HCM in the entire study population was 1.1%. The presence of physical symptoms was not associated with HCM (chest pain in 4.3% of participants with HCM vs. 9.9% of the control, P = 0.19, palpitation in 4.3% of participants with HCM vs. 7.3% of the control, P = 0.41, shortness of breath in 6.4% of participant with HCM vs. 11.7% of the control, P = 0.26, lightheadedness in 4.3% of participant with HCM vs. 13.1% of the control, P = 0.07, ankle swelling in 2.1% of participant with HCM vs. 4.0% of the control, P = 0.52, dizziness in 8.5% of participant with HCM vs. 12.2% of the control, P = 0.44).

Conclusions: Echocardiographic presence of suspected HCM is not associated with a higher prevalence of physical symptoms in the participants undergoing screening echocardiography.

查看原文本刊更多论文

超声心动图筛查中报告的身体症状与疑似肥厚型心肌病无关。

背景：肥厚型心肌病（HCM）的发病率可能很低，也可能以猝死为首发症状。本研究的目的是评估报告的身体症状与疑似肥厚性心肌病之间的关联：安东尼-贝茨基金会自 2001 年起在全美开展超声心动图筛查，以预防猝死。共有 4,120 名年龄在 6 岁至 79 岁之间的受试者接受了超声心动图筛查。我们评估了任何症状与疑似 HCM（定义为任何左心室壁厚度 ³ 15 mm）之间的关联：整个研究人群中疑似 HCM 的总发病率为 1.1%。身体症状的存在与 HCM 无关（4.3% 的 HCM 患者出现胸痛，而对照组为 9.9%，P=0.19；4.3% 的 HCM 患者出现心悸，而对照组为 7.3%，P=0.41；6.4% 的 HCM 患者出现气短，而对照组为 11.7%，P=0.26；头晕，而对照组为 11.7%，P=0.26）、P=0.26，4.3%的 HCM 患者出现头晕，对照组为 13.1%，P=0.07，2.1%的 HCM 患者出现脚踝肿胀，对照组为 4.0%，P=0.52，8.5%的 HCM 患者出现头晕，对照组为 12.2%，P=0.44）：结论：在接受超声心动图筛查的参与者中，超声心动图检查发现疑似 HCM 与较高的身体症状发生率无关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Critical Pathways in Cardiology Medicine-Medicine (all)

CiteScore

1.90

自引率

0.00%

发文量

期刊介绍： Critical Pathways in Cardiology provides a single source for the diagnostic and therapeutic protocols in use at hospitals worldwide for patients with cardiac disorders. The Journal presents critical pathways for specific diagnoses—complete with evidence-based rationales—and also publishes studies of these protocols" effectiveness.